Appendix F: Relative effects on outcomes of all pairs of interventions in Odds Ratios (95% credible intervals) as calculated from the network meta-analyses using fixed effects models

Virologic Response: HBeAg-positive population in the left lower triangle & HBeAg-negative population in the right upper triangle

	ADV	ADV2	ADVTBV	ETV	ETVTDF	LAM	LAMADV1	LAMADV2	LAMTBV	TBV	PLA	TAF	TDF
ADV				1.83 (0.06, 20.24)	1.53 (0.04, 23.82)	0.38 (0.01, 4)				1.34 (0.04, 14.84)	0.01 (0, 0.06)	11.01 (4.15, 28.96)	9.25 (5.61, 15.76)
ADV2	0.43 (0.26, 0.68)												
ADVTBV	0.39 (0.18, 0.86)	0.92 (0.36, 2.31)											
ETV	0.15 (0.09, 0.25)	0.36 (0.18, 0.71)	0.39 (0.17, 0.87)		0.85 (0.23, 3.09)	0.21 (0.14, 0.3)				0.73 (0.41, 1.3)	0.01 (0, 0.02)	6.1 (0.45, 211.59)	5.1 (0.43, 172.22)
ETVTDF	0.08 (0.04, 0.18)	0.2 (0.08, 0.49)	0.22 (0.08, 0.59)	0.56 (0.31, 0.99)		0.24 (0.06, 0.96)				0.86 (0.21, 3.68)	0.01 (0, 0.04)	7.32 (0.39, 307.99)	6.11 (0.38, 244.89)
LAM	0.43 (0.26, 0.74)	1.02 (0.5, 2.08)	1.12 (0.5, 2.48)	2.87 (2.28, 3.61)	5.12 (2.76, 9.57)					3.55 (2.34, 5.41)	0.03 (0.01, 0.09)	29.52 (2.29, 1013.11)	24.54 (2.19, 818.3)
LAMADV1	0.2 (0.1, 0.4)	0.47 (0.2, 1.11)	0.51 (0.21, 1.32)	1.33 (0.79, 2.21)	2.36 (1.09, 5.13)	0.46 (0.29, 0.73)							
LAMADV2	0.25 (0.12, 0.51)	0.58 (0.24, 1.39)	0.63 (0.24, 1.64)	1.63 (0.92, 2.82)	2.89 (1.3, 6.46)	0.57 (0.34, 0.93)	1.23 (0.74, 2.03)						
LAMTBV	0.3 (0.11, 0.8)	0.71 (0.24, 2.08)	0.77 (0.25, 2.41)	1.99 (0.85, 4.66)	3.55 (1.26, 9.88)	0.69 (0.31, 1.59)	1.5 (0.59, 3.89)	1.23 (0.47, 3.22)					
TBV	0.21 (0.12, 0.36)	0.49 (0.24, 1.01)	0.54 (0.24, 1.18)	1.38 (1, 1.88)	2.45 (1.28, 4.73)	0.48 (0.38, 0.6)	1.04 (0.63, 1.73)	0.85 (0.49, 1.48)	0.69 (0.31, 1.54)		0.01 (0, 0.03)	8.34 (0.62, 296.8)	6.98 (0.6, 235.54)
PLA	66.06 (11.69, 1836.09)	155.05 (27.71, 4296.41)	172.34 (24.81, 5073.69)	438.04 (70.47, 12724.24)	801.05 (113.8, 22781.85)	153.64 (24.45, 4417.57)	335.63 (49.87, 9966.97)	271.94 (40.04, 7927.08)	225.07 (29.73, 6855.64)	319.93 (50.92, 9248.77)		1058.56 (138.32, 32609.98)	874.13 (140.77, 26039.89)
TAF	0.08 (0.05, 0.13)	0.19 (0.09, 0.38)	0.2 (0.08, 0.5)	0.52 (0.31, 0.9)	0.94 (0.43, 2.07)	0.18 (0.1, 0.32)	0.39 (0.19, 0.83)	0.32 (0.15, 0.7)	0.26 (0.1, 0.71)	0.38 (0.21, 0.69)	0 (0, 0.01)		0.84 (0.38, 1.94)
TDF	0.07 (0.05, 0.11)	0.16 (0.09, 0.31)	0.18 (0.08, 0.42)	0.46 (0.29, 0.73)	0.82 (0.4, 1.7)	0.16 (0.1, 0.26)	0.35 (0.18, 0.69)	0.28 (0.14, 0.58)	0.23 (0.09, 0.6)	0.33 (0.2, 0.56)	0 (0, 0.01)	0.88 (0.65, 1.18)	

ALT Normalization: HBeAg-positive population in the left lower triangle & HBeAg-negative population in the right upper triangle

	ADV	ADV2	ADVTBV	ETV	ETVTDF	LAM	LAMADV1	LAMADV2	LAMTBV	TBV	PLA	TAF	TDF
ADV				3.52 (1.07, 12.41)	3.01 (0.64, 14.38)	2.29 (0.72, 7.7)				3.6 (1.08, 12.99)	0.15 (0.07, 0.3)	2.19 (1.24, 3.9)	1.03 (0.71, 1.5)

ADV	ADV2	ADVTBV	ETV	ETVTDF	LAM	LAMADV1	LAMADV2	LAMTBV	TBV	PLA	TAF	TDF
0.79 (0.52, 1.21)	**ADV2**											
0.66 (0.22, 1.75)	0.83 (0.26, 2.38)	**ADVTBV**										
0.53 (0.33, 0.85)	0.67 (0.37, 1.23)	0.81 (0.29, 2.44)	**ETV**	0.85 (0.32, 2.18)	0.65 (0.46, 0.91)				1.02 (0.6, 1.75)	0.04 (0.01, 0.11)	0.62 (0.16, 2.32)	0.29 (0.08, 1.03)
1.33 (0.64, 2.79)	1.68 (0.74, 3.88)	2.06 (0.64, 7.06)	2.49 (1.42, 4.48)	**ETVTDF**	0.77 (0.28, 2.14)				1.2 (0.41, 3.63)	0.05 (0.01, 0.2)	0.74 (0.14, 3.85)	0.34 (0.07, 1.71)
0.89 (0.55, 1.45)	1.13 (0.62, 2.05)	1.36 (0.5, 4.05)	1.67 (1.3, 2.16)	0.67 (0.35, 1.24)	**LAM**				1.57 (1.05, 2.38)	0.07 (0.02, 0.16)	0.95 (0.25, 3.44)	0.45 (0.13, 1.52)
0.39 (0.2, 0.76)	0.49 (0.23, 1.06)	0.6 (0.19, 1.98)	0.73 (0.43, 1.25)	0.29 (0.13, 0.64)	0.44 (0.27, 0.7)	**LAMADV1**						
0.3 (0.14, 0.64)	0.38 (0.16, 0.88)	0.46 (0.14, 1.6)	0.57 (0.3, 1.07)	0.23 (0.09, 0.53)	0.34 (0.19, 0.61)	0.78 (0.41, 1.44)	**LAMADV2**					
0.73 (0.24, 2.15)	0.92 (0.29, 2.86)	1.12 (0.27, 4.79)	1.37 (0.49, 3.76)	0.55 (0.17, 1.73)	0.82 (0.3, 2.17)	1.86 (0.62, 5.6)	2.41 (0.75, 7.57)	**LAMTBV**				
0.6 (0.35, 0.99)	0.75 (0.4, 1.4)	0.91 (0.33, 2.73)	1.12 (0.8, 1.57)	0.45 (0.23, 0.86)	0.67 (0.53, 0.84)	1.53 (0.91, 2.59)	1.97 (1.05, 3.77)	0.82 (0.31, 2.21)	**TBV**	0.04 (0.01, 0.11)	0.61 (0.15, 2.32)	0.29 (0.08, 1.02)
5.61 (3.57, 9.08)	7.08 (4.39, 11.93)	8.61 (2.94, 27.22)	10.53 (6.08, 18.52)	4.21 (1.88, 9.39)	6.29 (3.69, 10.98)	14.43 (7.02, 29.99)	18.65 (8.3, 41.97)	7.71 (2.55, 23.82)	9.42 (5.33, 17.08)	**PLA**	14.58 (5.94, 36.84)	6.84 (3.15, 15.58)
0.47 (0.29, 0.78)	0.6 (0.31, 1.12)	0.72 (0.24, 2.3)	0.89 (0.53, 1.48)	0.35 (0.16, 0.76)	0.53 (0.31, 0.91)	1.21 (0.59, 2.49)	1.56 (0.7, 3.52)	0.64 (0.21, 2)	0.79 (0.44, 1.42)	0.08 (0.04, 0.16)	**TAF**	0.47 (0.31, 0.72)
0.68 (0.45, 1.02)	0.86 (0.48, 1.52)	1.03 (0.37, 3.19)	1.27 (0.83, 1.96)	0.51 (0.25, 1.03)	0.76 (0.48, 1.22)	1.74 (0.9, 3.39)	2.25 (1.06, 4.8)	0.93 (0.32, 2.8)	1.14 (0.69, 1.9)	0.12 (0.07, 0.21)	1.44 (1.08, 1.93)	**TDF**

HBeAg seroconversion in the left lower triangle & **HBeAg loss** in the right upper triangle												
ADV	1.17 (0.72, 1.9)	1.19 (0.48, 2.86)	1.05 (0.6, 1.81)	0.69 (0.32, 1.47)	0.99 (0.58, 1.71)	0.99 (0.47, 2.1)	0.96 (0.42, 2.1)	0.54 (0.17, 1.62)	1.38 (0.79, 2.44)	0.38 (0.22, 0.64)	2.06 (0.99, 4.35)	1.74 (0.96, 3.21)
0.88 (0.47, 1.63)	**ADV2**	1.03 (0.37, 2.73)	0.89 (0.45, 1.79)	0.59 (0.25, 1.38)	0.85 (0.43, 1.69)	0.85 (0.36, 1.99)	0.82 (0.33, 2)	0.46 (0.13, 1.49)	1.18 (0.59, 2.38)	0.33 (0.18, 0.57)	1.77 (0.75, 4.21)	1.5 (0.71, 3.14)
0.88 (0.36, 2.19)	1 (0.35, 2.94)	**ADVTBV**	0.88 (0.36, 2.21)	0.58 (0.21, 1.67)	0.83 (0.35, 2.05)	0.83 (0.3, 2.36)	0.8 (0.28, 2.34)	0.45 (0.12, 1.65)	1.16 (0.49, 2.83)	0.32 (0.12, 0.87)	1.74 (0.59, 5.19)	1.46 (0.55, 4.03)
1.07 (0.67, 1.72)	1.21 (0.58, 2.55)	1.21 (0.47, 3.01)	**ETV**	0.66 (0.4, 1.1)	0.95 (0.72, 1.25)	0.95 (0.53, 1.69)	0.92 (0.47, 1.73)	0.52 (0.17, 1.41)	1.32 (0.93, 1.89)	0.37 (0.19, 0.67)	1.98 (1.01, 3.9)	1.66 (0.99, 2.81)

1.88 (0.9, 3.92)	2.13 (0.84, 5.43)	2.14 (0.72, 6.19)	1.75 (1.02, 3.06)	**ETVTDF**	1.43 (0.8, 2.56)	1.43 (0.66, 3.1)	1.38 (0.6, 3.12)	0.77 (0.24, 2.42)	1.99 (1.08, 3.75)	0.55 (0.25, 1.23)	2.99 (1.28, 7.01)	2.52 (1.22, 5.23)	
1.11 (0.7, 1.78)	1.26 (0.61, 2.62)	1.26 (0.5, 3.07)	1.04 (0.79, 1.37)	0.59 (0.32, 1.1)	**LAM**	1 (0.6, 1.66)	0.97 (0.53, 1.72)	0.54 (0.19, 1.42)		0.39 (0.21, 0.7)	2.09 (1.03, 4.25)	1.76 (0.99, 3.1)	
0.37 (0.17, 0.81)	0.42 (0.15, 1.12)	0.42 (0.13, 1.31)	0.35 (0.15, 0.77)	0.2 (0.07, 0.53)	0.34 (0.15, 0.72)	**LAMADV**							
1.31 (0.63, 2.76)	1.5 (0.59, 3.78)	1.49 (0.51, 4.26)	1.23 (0.65, 2.33)	0.7 (0.3, 1.63)	1.18 (0.67, 2.11)	3.53 (1.35, 9.46)	**LAMADV1**	0.96 (0.53, 1.73)	0.54 (0.17, 1.61)	1.4 (0.8, 2.44)	0.39 (0.18, 0.84)	2.09 (0.87, 5.03)	1.76 (0.82, 3.78)
1.48 (0.66, 3.44)	1.69 (0.63, 4.64)	1.69 (0.54, 5.14)	1.39 (0.67, 2.94)	0.79 (0.31, 2.02)	1.34 (0.68, 2.69)	4 (1.44, 11.62)	1.13 (0.57, 2.3)	**LAMADV2**	0.56 (0.17, 1.75)	1.45 (0.78, 2.74)	0.4 (0.17, 0.93)	2.16 (0.86, 5.47)	1.82 (0.82, 4.18)
2.14 (0.71, 7.17)	2.45 (0.69, 9.31)	2.43 (0.64, 10.03)	2 (0.7, 6.46)	1.14 (0.35, 4.14)	1.92 (0.71, 6.01)	5.75 (1.62, 22.87)	1.63 (0.51, 5.74)	1.44 (0.42, 5.36)	**LAMTBV**	2.57 (1, 7.27)	0.72 (0.23, 2.35)	3.87 (1.18, 13.66)	3.25 (1.07, 10.66)
0.8 (0.48, 1.33)	0.91 (0.43, 1.94)	0.91 (0.37, 2.21)	0.75 (0.52, 1.09)	0.43 (0.22, 0.83)	0.72 (0.57, 0.93)	2.16 (0.97, 4.92)	0.61 (0.33, 1.14)	0.54 (0.26, 1.1)	0.38 (0.12, 1.01)	**TBV**	0.28 (0.15, 0.52)	1.49 (0.72, 3.12)	1.26 (0.69, 2.31)
2.9 (1.58, 5.49)	3.3 (1.6, 7.08)	3.29 (1.16, 9.31)	2.72 (1.47, 5.21)	1.55 (0.68, 3.68)	2.61 (1.47, 4.85)	7.83 (3.09, 20.6)	2.22 (0.98, 5.13)	1.96 (0.79, 4.88)	1.36 (0.38, 4.43)	3.61 (1.95, 7.01)	**PLA**	5.42 (2.33, 12.56)	4.56 (2.22, 9.49)
0.55 (0.28, 1.09)	0.63 (0.25, 1.55)	0.63 (0.21, 1.84)	0.52 (0.26, 1.04)	0.3 (0.12, 0.72)	0.5 (0.24, 1.01)	1.49 (0.55, 4.12)	0.42 (0.17, 1.06)	0.37 (0.14, 0.99)	0.26 (0.07, 0.89)	0.69 (0.32, 1.46)	0.19 (0.08, 0.45)	**TAF**	0.84 (0.54, 1.29)
0.73 (0.46, 1.15)	0.83 (0.39, 1.74)	0.83 (0.31, 2.15)	0.68 (0.42, 1.1)	0.39 (0.19, 0.81)	0.66 (0.39, 1.1)	1.97 (0.83, 4.75)	0.56 (0.26, 1.2)	0.49 (0.21, 1.15)	0.34 (0.1, 1.06)	0.91 (0.52, 1.58)	0.25 (0.12, 0.5)	1.31 (0.8, 2.21)	**TDF**

HBsAg loss for HBeAg-positive population

ADV	2.9 (0.05, 271.54)	3.85 (0.03, 640.68)	1.85 (0.01, 329.3)	1.69 (0, 1130.85)	1.8 (0, 1261.02)	1.8 (0.01, 494.34)	0.66 (0, 332.63)	13.33 (0.19, 2314.97)	4.41 (0.25, 178.38)
0.34 (0, 22.06)	**ETV**	1.31 (0.11, 15.76)	0.63 (0.05, 7.79)	0.58 (0.01, 63.34)	0.59 (0, 65.36)	0.61 (0.02, 15.05)	0.23 (0, 15.45)	4.53 (0.07, 557.31)	1.58 (0.09, 30.77)

0.26 (0, 32.13)	0.76 (0.06, 9.37)	**ETVTDF**	0.48 (0.01, 17.23)	0.43 (0, 89.87)	0.45 (0, 97.49)	0.47 (0.01, 26.73)	0.17 (0, 20.11)	3.47 (0.03, 718.78)	1.18 (0.03, 56.56)
0.54 (0, 77.74)	1.59 (0.13, 20.71)	2.1 (0.06, 75.21)	**LAM**	0.93 (0.02, 49.96)	0.94 (0.02, 52.48)	0.98 (0.13, 7.42)	0.38 (0.01, 9.99)	7.24 (0.06, 1694.37)	2.53 (0.05, 129.33)
0.59 (0, 325.27)	1.73 (0.02, 198.06)	2.3 (0.01, 483.26)	1.08 (0.02, 61.42)	**LAMADV1**	1.03 (0.02, 61.82)	1.05 (0.01, 98.11)	0.39 (0, 76.6)	8.2 (0.01, 6590.4)	2.86 (0.01, 665.43)
0.56 (0, 323.9)	1.7 (0.02, 206.83)	2.23 (0.01, 498.84)	1.07 (0.02, 62.58)	0.97 (0.02, 61.37)	**LAMADV2**	1.01 (0.01, 94.99)	0.39 (0, 76.92)	7.85 (0.01, 6778.66)	2.7 (0.01, 693.81)
0.55 (0, 114.71)	1.64 (0.07, 44.14)	2.12 (0.04, 136.67)	1.02 (0.13, 7.72)	0.96 (0.01, 88.89)	0.99 (0.01, 84.19)	**TBV**	0.38 (0, 17.85)	7.4 (0.04, 2548.22)	2.61 (0.03, 211.32)
1.5 (0, 821.17)	4.35 (0.06, 468.91)	5.75 (0.05, 1160.17)	2.67 (0.1, 134.84)	2.53 (0.01, 655.63)	2.57 (0.01, 747.77)	2.64 (0.06, 208.83)	**PLA**	20.47 (0.05, 15819.77)	6.86 (0.04, 1758.07)
0.08 (0, 5.39)	0.22 (0, 15.21)	0.29 (0, 39.2)	0.14 (0, 18.17)	0.12 (0, 67.34)	0.13 (0, 67.65)	0.14 (0, 27.08)	0.05 (0, 18.71)	**TAF**	0.37 (0.01, 7.23)
0.23 (0.01, 4.01)	0.63 (0.03, 11.07)	0.84 (0.02, 35.92)	0.4 (0.01, 18.37)	0.35 (0, 89.03)	0.37 (0, 87.88)	0.38 (0, 29.05)	0.15 (0, 23.22)	2.67 (0.14, 127.9)	**TDF**

Footnotes: Treatments are reported in alphabetical order.
Empty cells in the right upper triangles are due to lack of studies comparing the treatment pairs in the virologic response and ALT normalization networks of the HBeAg-negative population; and the lack of studies comparing the treatment pairs in the HBeAg loss network.
Data are reported as an odds ratio (95% CI). Odd ratios higher than 1 favor the column-defining treatment.
Significant results are in red.

Abbreviations: HBeAg seroconversion, hepatitis B e antigen seroconversion; HBeAg loss, hepatitis B e antigen loss; HBsAg loss, hepatitis B surface antigen loss; ADV, adefovir 10mg daily; ADV2, adefovir 30mg daily; ETV, entecavir; LAM, lamivudine; TBV, telbivudine; PLA, placebo; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ADVTBV, ETVTDF, LAMADV, LAMADV1, LAMADV2, and LAMTBV code for different combinations of antiviral agents with full details in Appendix C.